The purpose of this study is to compare the efficacy and safety of everolimus- and biolimus-bluting stents with everolimus-eluting bioresorbable vascular scaffold stents. The null hypothesis to be rejected is that there is no significant difference with regard to lumen late loss at 9 months and a clinical end point of death, myocardial infarction and TVR at 12 months between everolimus-eluting and biolimus-eluting stents and everolimus-eluting bioresorbable vascular scaffold stents.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
240
Fribourg Cantonal Hospital
Fribourg, Switzerland
Lumen Late Loss
as assessed by quantitative coronary angiogram
Time frame: 9 months
Device-oriented major adverse cardiac events
The composite of cardiac death, myocardial infarction (not clearly attributable to a nontarget vessel) and target lesion revascularization
Time frame: 6 months, 1, 2, 5 years
Patient-oriented major adverse cardiac events
The composite of all-cause mortality, any myocardial infarction and any revascularization
Time frame: 6 months, 1, 2, 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.